Lead asset for acute myeloid leukemia (AML) on track for IND filing in 2026; second asset for solid tumor(s) entering IND-enabling studies Novel platform leverages proprietary cell stress sensing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results